肖志坚 . 我国骨髓增殖性肿瘤的诊治现状及挑战[J]. 诊断学理论与实践, 2020 , 19(02) : 101 -103 . DOI: 10.16150/j.1671-2870.2020.02.001
| [1] | 肖志坚. 进一步规范我国骨髓增殖性肿瘤的诊断和治疗[J]. 中国实用内科杂志, 2018, 38(2):89-92. |
| [2] | 中华医学会血液学分会白血病淋巴瘤学组. 原发性骨髓纤维化诊断与治疗中国指南(2019年版)[J]. 中华血液学杂志, 2019, 40(1):1-7. |
| [3] | 徐泽锋, 李冰, 刘晋琴, 等. JAK2、MPL和CALR基因突变在中国原发性骨髓纤维化患者中的预后意义[J]. 中华血液学杂志, 2016, 37(7):576-580. |
| [4] | Li B, Gale RP, Xu Z, et al. Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis[J]. J Hematol Oncol, 2017, 10(1):99. |
| [5] | 徐俊卿, 徐泽锋, 王静雅, 等. 615例Ph染色体/BCR-ABL融合基因阴性骨髓增殖性肿瘤患者的症状负荷评估[J]. 中华血液学杂志, 2016, 37(1):26-29. |
| [6] | 中华医学会血液学分会白血病淋巴瘤学组. 真性红细胞增多症诊断与治疗中国专家共识(2016年版)[J]. 中华血液学杂志, 2016, 37(4):265-268. |
| [7] | 中华医学会血液学分会白血病淋巴瘤学组. 原发性血小板增多症诊断与治疗中国专家共识(2016年版)[J]. 中华血液学杂志, 2016, 37(10):833-836. |
| [8] | Luo X, Xu Z, Li B, et al. Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response[J]. Blood Cancer J, 2018, 8(1):9. |
| [9] | 肖志坚. 我如何治疗原发性骨髓纤维化[J]. 中华血液学杂志, 2019, 40(3):179-181. |
| [10] | Li B, Rampal RK, Xiao Z. Targeted therapies for myeloproliferative neoplasms[J]. Biomark Res, 2019, 7:15. |
| [11] | 张瑜堤, 徐泽锋, 肖志坚. 免疫调节剂治疗骨髓纤维化研究进展[J]. 中国实用内科杂志, 2019, 39(3):67-72. |
| [12] | 吴君颖, 肖志坚. 原发性骨髓纤维化预后评分系统的研究现状[J]. 国际输血及血液学杂志, 2019, 42(4):277-282. |
| [13] | Xiao Z, Zhang Y, Li L, et al. The Janus kinase 2 (JAK2) V617F mutation in Chinese patients with chronic myeloproliferative disorders[J]. Haematologica, 2008, 93(5):787-788. |
| [14] | Xu Z, Gale RP, Zhang Y, et al. Unique features of primary myelofibrosis in Chinese[J]. Blood, 2012, 119(11):2469-2473. |
| [15] | Wang J, Xu Z, Liu L, et al. JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms[J]. Leukemia, 2013, 27(8):1763-1767. |
| [16] | Li B, Xu J, Wang J, et al. Calreticulin mutations in Chinese with primary myelofibrosis[J]. Haematologica, 2014, 99(11):1697-1700. |
| [17] | Li B, Xu J, Li C, et al. Cytogenetic studies and their prognostic contribution in 565 Chinese patients with primary myelofibrosis[J]. Am J Hematol, 2014, 89(11):1043-1046. |
| [18] | Li B, Xu Z, Li Y, et al. The different prognostic impact of type-1 or type-1 like and type-2 or type-2 like CALR mutations in patients with primary myelofibrosis[J]. Am J Hematol, 2016, 91(7):E320-E321. |
| [19] | Li B, Zhang P, Feng G, et al. Bone marrow fibrosis grade is an independent risk factor for overall survival in patients with primary myelofibrosis[J]. Blood Cancer J, 2016, 6(12):e505. |
/
| 〈 |
|
〉 |
